A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014 May; 4(5):554-63.